Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s share price fell 0% during trading on Friday . The stock traded as low as $0.32 and last traded at $0.32. 689,712 shares traded hands during trading, a decline of 76% from the average session volume of 2,830,671 shares. The stock had previously closed at $0.32.
Several brokerages have commented on ANTH. Zacks Investment Research raised Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Tuesday, February 27th. HC Wainwright reissued a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Tuesday, March 6th. Roth Capital began coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine raised Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $4.06.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.09. research analysts forecast that Anthera Pharmaceuticals Inc will post -1.68 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. 683 Capital Management LLC purchased a new position in shares of Anthera Pharmaceuticals in the 4th quarter worth about $399,000. BVF Inc. IL raised its position in shares of Anthera Pharmaceuticals by 20.9% in the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after purchasing an additional 209,896 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of Anthera Pharmaceuticals in the 4th quarter worth about $1,269,000. 16.65% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/anthera-pharmaceuticals-anth-shares-down-0.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.